Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız:
http://hdl.handle.net/11452/24943
Başlık: | Therapy, outcome and analysis of c-kit expression in patients with extrapulmonary small cell carcinoma |
Yazarlar: | Sezgin, Canfeza Veral, Ali Karabulut, Bülent Göker, Erdem Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı. Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı. 0000-0002-2382-290X 0000-0003-2501-3097 0000-0002-9732-5340 Kurt, Ender Evrensel, Türkkan Yalçınkaya, Ülviye Kanat, Özkan Demiray, Mutlu Arslan, Murat Ercan, İlker Manavoǧlu, Osman M-8060-2019 AAJ-1027-2021 7006207332 6603942124 6508300295 55881548500 6603631569 57197925370 6603789069 6602587152 |
Anahtar kelimeler: | General & internal medicine Pharmacology & pharmacy Extrapulmonary Small cell carcinoma Therapy C-kit Single-institution experience Lung-cancer Protein expression Phase-II Chemotherapy Bladder Overexpression Prognosis Diagnosis Imatinib |
Yayın Tarihi: | May-2005 |
Yayıncı: | Wiley |
Atıf: | Kurt, E. vd. (2005). "Therapy, outcome and analysis of c-kit expression in patients with extrapulmonary small cell carcinoma". International Journal of Clinical Practice, 59(5), 537-543. |
Özet: | In this study, we aimed to investigate the clinicopathological characteristics with special emphasis on c-kit expression and the treatment results of patients with extrapulmonary small cell carcinoma (EPSCC). The medical records of the patients with EPSCC were reviewed, and the data regarding patient and tumour characteristics, treatment and clinical outcome were retrieved and analysed. A total of 28 patients with the diagnosis of EPSCC were identified. There were 19 males and 9 females, with a mean age of 56.5 years. Patients with limited disease (LD) (n = 13) were treated with surgery, chemotherapy (CT) and radiotherapy with different sequences. Patients with extensive disease (ED) (n = 15) were mainly treated with combination CT. The median overall survival was 14.5 months in patients with LD compared to 11 months in those with ED (p = 0.029). Ten patients (36%) showed c-kit overexpression. There was no significant difference between the survival of c-kit-positive and c-kit-negative patients (p = 0.367). In conclusion, our study demonstrates that the prognosis of EPSCC is poor despite currently available treatments. C-kit may be considered as a potential target for novel therapeutical approaches. |
URI: | https://doi.org/10.1111/j.1368-5031.2005.00447.x https://onlinelibrary.wiley.com/doi/10.1111/j.1368-5031.2005.00447.x https://pubmed.ncbi.nlm.nih.gov/15857349/ http://hdl.handle.net/11452/24943 |
ISSN: | 1368-5031 |
Koleksiyonlarda Görünür: | PubMed Scopus Web of Science |
Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.
Bu öğe kapsamında lisanslı Creative Commons License